• Legend Biotech priced an underwritten public offering of 7,700,000 ADSs at USD 29.35 per ADS.
• Gross proceeds expected at about USD 226 million before fees, excluding any option exercise.
• Underwriters hold a 30-day option to buy up to 1,155,000 additional ADSs.
• Closing expected June 23, 2026, subject to customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277556), on June 22, 2026, and is solely responsible for the information contained therein.